NCT06905262 Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)
| NCT ID | NCT06905262 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Naples |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2023-01-02 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2023-01-02 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: From Benchside to Bedside (HepAnt) - Study of the Role of the Metagenome in Head and Neck Tumors Using Omics Techniques (HeNomics).
Eligibility Criteria
Inclusion Criteria: * Histological diagnosis of primary HCC and other oncological pathology (Pascale Institute) or diagnosis of oncological pathology (without any exclusions) from an accredited medical-clinical facility (Fortore Mountain Community). * Age ≥18 years * Ability to give signed informed consent that includes compliance with the requirements and constraints listed in the informed consent form (ICF) and in this protocol. * In the case of paraffin-embedded samples obtained from the UOC of Pathological Anatomy and/or the Institute's Biological Bank, informed consent cannot be acquired, in accordance with the Provision of the Privacy Authority containing the requirements relating to the processing of special categories of data, pursuant to art. 21, paragraph 1 of Legislative Decree 10 August 2018, no. 101, published in the Official Journal - general series - no. 176 of 29/07/2019, point 5 "Provisions relating to the processing of personal data carried out for scientific research purposes (gen. aut. n. 9/2016)" HEALTHY SUBJECTS * clinical history free from diagnosis of tumor or neoplastic pathology treated during life * Age ≥80 years * Ability to give signed informed consent that includes compliance with the requirements and constraints listed in the informed consent form (ICF) and in this protocol Exclusion Criteria: * Current pathologies requiring antibiotic therapy * Diagnosis of pre-tumor pathology (in healthy subjects)
Contact & Investigator
Luigi Buonaguro
PRINCIPAL INVESTIGATOR
IRCCS I.N.T. "G. Pascale"
Frequently Asked Questions
Who can join the NCT06905262 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06905262 currently recruiting?
Yes, NCT06905262 is actively recruiting participants. Contact the research team at l.buonaguro@istitutotumori.na.it for enrollment information.
Where is the NCT06905262 trial being conducted?
This trial is being conducted at Naples, Italy.
Who is sponsoring the NCT06905262 clinical trial?
NCT06905262 is sponsored by National Cancer Institute, Naples. The principal investigator is Luigi Buonaguro at IRCCS I.N.T. "G. Pascale". The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.